Christine Benn Christiansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christine Benn Christiansen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Adelina Yafasova
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark
1 shared publicationChristian Torp-Pedersen
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
1 shared publication- Christian Torp-Pedersen
Copenhagen University Hospital, Steno Diabetes Center Copenhagen Herlev Denmark
1 shared publication Christina Kruuse
Department of Neurology, Herlev-Gentofte University Hospital, Denmark
1 shared publicationEmil Fosbøl
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
1 shared publicationEmil L. Fosbøl
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-9
Severity of Gastrointestinal Bleeding in Anticoagulant Therapy with Vitamin K Antagonist or Direct Oral Anticoagulant Therapy
Background: It remains undetermined whether gastrointestinal bleeding (GIB) associated with direct oral anticoagulant (DOAC) or vitamin K antagonists (VKA) is more severe. Methods: In Danish nationwide registries, we identified patients with atrial fibrillation (AF) treated with anticoagulation with gastrointestinal bleeding (GIB). Logistic regression models were used to compare GIB severity between DOAC and VKA users, defined by 1. red blood cell transfusion or in-hospital death and 2. endoscopies. Results: From 2012–2018, 6,784 anticoagulated AF patients with GIB were identified; 3,724 patients VKA users and 3,060 DOAC (apixaban, dabigatran or rivaroxaban) users. The proportion of upper GIB was 49% in VKA users and 40.1% in DOAC users. Blood transfusions were administered to 58.2% and 43.8–48.9% of patients with VKA and DOAC, respectively. Odds ratios (OR, adjusted for age, sex, and comorbidities) for severe GIB were significantly reduced for all DOACs compared to VKA (apixaban 0.71 (95% confidence interval (CI) 0.59–0.85), dabigatran 0.64 (95% CI 0.55–0.75) and rivaroxaban 0.69 (95% CI 0.59–0.81)). Odds for endoscopy was significantly reduced in apixaban (OR 0.77 (95% CI 0.65–0.90) and dabigatran (OR 0.81 (95% CI 0.71–0.93) compared to VKA, and borderline reduced for rivaroxaban (OR 0.88 (95% CI 0.77–1.02)). In patients with upper GIB, compared to VKA the use of gastroscopy was significantly reduced for apixaban (0.68 (95% CI 0.53–0.87)) but not for dabigatran or rivaroxaban. Conclusion: VKA use was associated with more severe GIB and more frequent endoscopies compared to DOAC. Future studies should identify subgroups at particular risk of severe GIB.
- 29 April 2026
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-9
Open AccessSeverity of Gastrointestinal Bleeding in Anticoagulant Therapy with Vitamin K Antagonist or Direct Oral Anticoagulant Therapy
Background: It remains undetermined whether gastrointestinal bleeding (GIB) associated with direct oral anticoagulant (DOAC) or vitamin K antagonists (VKA) is more severe. Methods: In Danish nationwide registries, we identified patients with atrial fibrillation (AF) treated with anticoagulation with gastrointestinal bleeding (GIB). Logistic regression models were used to compare GIB severity between DOAC and VKA users, defined by 1. red blood cell transfusion or in-hospital death and 2. endoscopies. Results: From 2012–2018, 6,784 anticoagulated AF patients with GIB were identified; 3,724 patients VKA users and 3,060 DOAC (apixaban, dabigatran or rivaroxaban) users. The proportion of upper GIB was 49% in VKA users and 40.1% in DOAC users. Blood transfusions were administered to 58.2% and 43.8–48.9% of patients with VKA and DOAC, respectively. Odds ratios (OR, adjusted for age, sex, and comorbidities) for severe GIB were significantly reduced for all DOACs compared to VKA (apixaban 0.71 (95% confidence interval (CI) 0.59–0.85), dabigatran 0.64 (95% CI 0.55–0.75) and rivaroxaban 0.69 (95% CI 0.59–0.81)). Odds for endoscopy was significantly reduced in apixaban (OR 0.77 (95% CI 0.65–0.90) and dabigatran (OR 0.81 (95% CI 0.71–0.93) compared to VKA, and borderline reduced for rivaroxaban (OR 0.88 (95% CI 0.77–1.02)). In patients with upper GIB, compared to VKA the use of gastroscopy was significantly reduced for apixaban (0.68 (95% CI 0.53–0.87)) but not for dabigatran or rivaroxaban. Conclusion: VKA use was associated with more severe GIB and more frequent endoscopies compared to DOAC. Future studies should identify subgroups at particular risk of severe GIB.
- Open Access
- 12 March 2026
- Published by Elsevier in Sleep Medicine
- Vol. 143, 108893
Association between continuous positive airway pressure usage and workforce attachment in obstructive sleep apnea
- 12 March 2026
- Published by Elsevier in Sleep Medicine
- Vol. 143, 108893
Open AccessAssociation between continuous positive airway pressure usage and workforce attachment in obstructive sleep apnea
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (11) , 106031
Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy
- 1 November 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (11) , 106031
Open AccessWorkforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy